Printer Friendly

Abbott awarded FDA approval for the new Abbott Vysis ALK Break Apart FISH Probe test for lung cancer.

M2 EQUITYBITES-August 29, 2011-Abbott awarded FDA approval for the new Abbott Vysis ALK Break Apart FISH Probe test for lung cancer(C)2011 M2 COMMUNICATIONS http://www.m2.com

Health company Abbott (NYSE:ABT) reported on Friday the receipt of approval from the US Food and Drug Administration (FDA) for a new molecular diagnostic test, called The new Abbott Vysis ALK Break Apart FISH Probe test, for lung cancer.

The company stated new Abbott Vysis ALK Break Apart FISH Probe test is designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) patients for its approved NSCLC therapy, XALKORI (crizotinib).

This diagnostic test offers clinicians a standardised, clinically validated method to identify patients more likely to benefit from the new therapy.

Following the receipt of the simultaneous FDA approvals, the company expects to change the clinical practice for the diagnosis and treatment of patients with NSCLC.

In conjunction, the company stated the Vysis ALK FISH test will be available to clinicians and pathologists through Abbott Molecular.

((Comments on this story may be sent to info@m2.com)).END.PUB430>PDAugust 29, 2011>JNM2 EQUITYBITES.PRICEDATENOT APPLICABLE.DAY

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Aug 29, 2011
Words:193
Previous Article:UQM announces collaboration with ReGen Nautic USA Inc to expand into marine propulsion industry.
Next Article:Ferrellgas Partners LP reports Q4 cash distribution of USD0.50 per common unit.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters